Agus, David B <br/><br/>
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 2007 
 - 675-81 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2006.07.0649  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Bridged-Ring Compounds--adverse effects<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Resistance, Neoplasm<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Orchiectomy<br/>Probability<br/>Prognosis<br/>Prostatic Neoplasms--drug therapy<br/>Receptor, ErbB-2--administration & dosage<br/>Risk Assessment<br/>Single-Blind Method<br/>Survival Analysis<br/>Taxoids--adverse effects<br/>Treatment Outcome